Is BMY a good stock to buy? We came across a bullish thesis on Bristol-Myers Squibb Company on MaxDividends’s Substack by Serhio MaxDividends. In this article, we will summarize the bulls’ thesis on BMY. Bristol-Myers Squibb Company’s share was trading at $59.43 as of March 26th. BMY’s trailing and forward P/E were 16.61 and 9.20 respectively according to Yahoo Finance.
Jirsak/Shutterstock.com
Bristol Myers Squibb (BMY) is a leading global biopharmaceutical company with a diversified portfolio focused on oncology, immunology, and cardiovascular diseases, making it a reliable dividend-paying stock for long-term investors. The company has a 17-year streak of consecutive dividend increases, currently yielding 4.63% with an annual payout of $2.52 per share, supported by strong free cash flow and profitability.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
BMY’s established products, including Opdivo and Eliquis, generate stable revenues even amid patent expirations, while its growth portfolio—featuring drugs like Reblozyl, Breyanzi, and late-stage candidates such as milvexian and admilparant—offers substantial upside potential. In 2024, BMY reported $48.3 billion in revenue, up 7% year-over-year, with non-GAAP EPS of $1.15, reflecting resilient operational performance. Strategic partnerships, including collaborations with BioNTech and AI-driven initiatives, further accelerate innovation and strengthen the pipeline.
The company balances scale with biotech-like scientific drive, investing heavily in R&D and planning over ten new product launches by 2030. Institutional backing from Vanguard, BlackRock, and State Street underscores confidence in BMY’s strategy and financial stability. While the business faces generic competition and occasional setbacks, its diversified revenue streams, robust pipeline, and commitment to scientific innovation mitigate risks, providing a resilient foundation for sustained growth and shareholder returns.
Analysts maintain a “Buy” consensus, with an average 12-month price target of $57.64, reflecting moderate upside potential. For investors seeking a combination of steady dividends, strong fundamentals, and long-term growth in a globally recognized pharmaceutical leader, Bristol Myers Squibb presents a compelling opportunity with limited downside risk.
Previously, we covered a bullish thesis on Bristol-Myers Squibb Company (BMY) by Magnus Ofstad in March 2025, which highlighted the company’s high-risk, high-reward growth potential driven by its neuroscience drug Cobenfy and broader pipeline. BMY’s stock price has appreciated by approximately 0.72% since our coverage. Serhio MaxDividends shares a similar view but emphasizes BMY’s reliable dividend track record, diversified portfolio, and steady long-term growth.
Bristol-Myers Squibb Company is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 82 hedge fund portfolios held BMY at the end of the fourth quarter which was 76 in the previous quarter. While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
